Future studies also need to focus on correlations between NFATc1 amplification and clinical outcomes, such as infection or subclinical rejection.[47] The present study included only one patient suffering from a rejection under TAC-based therapy, which makes it impossible to draw conclusions on the association between NFATc1 amplification and rejection risk. This evidence concerns the gene NFATC1 and infection.